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Abstract: This editorial aims to summarize the 19 scientific papers that contributed to the Special 
Issue “Adipokines 2”. 
 
The Special Issue, “Adipokines 2.0” of the International Journal of Molecular Sciences is a follow 
up of the Special Issue “Adipokines” published two years ago.  
Proteins secreted from fat tissues are collectively referred to as adipokines. Circulating levels of 
these proteins are—with a few exceptions—increased in obesity. Hundreds of adipokines were 
discovered and annexins, well known as regulators of membrane-related events such as exocytosis, 
may affect adipokine release from fat tissues [1].  
Adipokines promote metabolic and cardiovascular diseases and are biomarkers for obesity-
associated comorbidities. Metabolically healthy obesity is associated with an adipokinome similar to 
that of normal weight mice, providing more evidence for a central role of adipose tissue produced 
proteins in metabolic diseases [2]. Weight loss improves the parameters of insulin sensitivity and 
hypertension, but most patients regain weight. Adipocytes cultivated in medium with low, and later 
on high glucose, showed a different secretome in comparison to the control cells. These differentially 
released proteins may contribute to worse metabolic parameters in obese patients after weight regain 
[3].  
Physical activity is linked to improved metabolic health in normal weight and obesity. Adipo-
myokines are proteins secreted by adipose tissues and skeletal muscle and seem to have a role herein. 
These molecules may be useful to classify different types of obesity and develop individualized 
therapeutic strategies [4].   
Excessive gestational weight gain increases the risk of neonatal and maternal complications. The 
adipokine secreted frizzled-related protein 5 (SFRP5) improves metabolic function. Serum as well as 
umbilical cord blood levels were low in women with an extreme increase in weight during pregnancy 
[5]. Leptin was higher in the serum and cord blood of male infants born from mothers with excessive 
gestational weight gain. Such an induction was not observed for female babies [6]. Adipokine levels 
correlated with neonatal anthropometric measurements and may contribute to greater risk of obesity 
and metabolic disease in later life [5,6]. 
Excess body weight is a risk factor for insulin resistance, hypertension, and cardiovascular 
diseases. Epicardial adipose tissue contributes to cardiac enlargement in the obese and this involves 
deregulation of prostaglandin E2 [7]. Overweight and obesity are, moreover, linked to a higher risk 
of different cancers [8,9]. This was studied in detail for the adipokine chemerin. Of note, chemerin 
was shown to impair and to improve insulin sensitivity, to have pro- and anti-inflammatory activities 
and to exert pro- and anticancer effects [8–10]. These antagonistic effects may be in part attributed to 
the different biologic activities of the chemerin isoforms [8]. The role of chemerin in cancer diseases 
was nicely summarized in two review articles [9,10]. An original investigation tested whether 
chemerin may serve as a biomarker to discriminate patients with primary and secondary liver 
tumors. This study identified an association of serum chemerin with hypertension and 
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hypercholesterolemia in the tumor patients [11]. Serum chemerin could, however, not distinguish 
patients with hepatocellular carcinoma and colorectal liver metastases [11].  
Adipokines are involved in the pathogenesis of reproductive disorders. The roles of chemerin, 
visfatin, resistin, and apelin in fertility and associated diseases were summarized in a review article 
with various informative and clear illustrations [12]. 
A potential role of chemerin in reproductive function was supported by the finding that plasma 
levels as well as the expression of its receptors, chemokine-like receptor 1, G protein-coupled receptor 
1, and C-C motif chemokine receptor-like 2 fluctuated throughout the estrous cycle and pregnancy 
in the porcine hypothalamus [13].  
Other approaches have been to determine the release of adipokines by tissues other than fat. 
One study analyzed the levels of chemerin, apelin, and omentin in follicular fluid and ovarian 
granulosa cells. Study cohorts were women with polycystic ovary syndrome, women with a 
polycystic ovary morphology, and the controls. Differential abundance of these adipokines in the 
patients suggested a possible role in the pathophysiology of polycystic ovary syndrome [14]. 
Adipokines are expressed by different cells in the joint microenvironment. Locally produced as 
well as systemic adipokines contribute to osteoarthritis and rheumatoid arthritis. Different studies 
have analyzed the pathophysiological role of various adipokines (e.g., adiponectin, leptin and so on). 
These studies were nicely summarized in a review article [15]. Interestingly, the serum levels of most 
of these adipokines were higher in the patients [15]. A separate study investigated the effect of 
treatment with the anti-interleukin-6 receptor antibody tocilizumab in patients with rheumatoid 
arthritis. Four months of therapy was associated with higher resistin levels and lower adiponectin 
whereas leptin was not altered [16]. After treatment, adiponectin and resistin serum concentrations 
were similar to the controls, suggesting the normalization of these parameters [16].  
Moreover, adipokines were also analyzed as potential biomarkers in sepsis and critical illness. 
Here, prospective studies are required to finally evaluate the prognostic relevance of the different 
proteins measured. The heterogeneity of these patient cohorts may limit the diagnostic potential of 
circulating adipokine levels [17].  
The role of adipose tissue in the pathophysiology of most diseases is greatly unknown. There is 
mounting evidence though that adipokines act in the brain, and the role of leptin in the control of 
food consumption has been well described. Adiponectin protected mice from high fat diet induced 
hypothalamic inflammation [18]. Microglia, as the resident macrophages of the central nervous 
system, expressed both adiponectin receptors and were essential for the protective activity of 
adiponectin [18]. 
The neuroprotective effects of the adipokines leptin, adiponectin, chemerin, apelin, and visfatin 
indicate a potential role for these molecules as therapeutic targets in neurodegenerative diseases [19]. 
Overall, these 19 contributions published in this Special Issue further strengthen the essential 
function of adipokines in health and in various diseases. Different adipose tissue depots may have 
specific functions and detailed analysis of their secretome may provide more insight into the 
connection between fad pads and physiology. 
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